Tasso Partners, LLC - 27 Mar 2026 Form 3 Insider Report for PAVmed Inc. (PAVM)

Reporting relationship: 10%+ Owner
Issuer ticker: PAVM
Reported as of: 27 Mar 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 06 Apr 2026, 21:46:16 UTC
Prior SEC filing: 14 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ Dana Carrera, as manager of managing member

Key filing fact

Tasso Partners, LLC filed Form 3 for PAVmed Inc. (PAVM) on 06 Apr 2026.

Key facts

This page summarizes Tasso Partners, LLC's Form 3 filing for PAVmed Inc. (PAVM).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Apr 2026, 21:46.

Change

Previous filing in this sequence was filed on 14 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001965743 Primary reporting owner

Tasso Partners, LLC

Relationship: 10%+ Owner
Address: P.O. BOX 6194, FAIR HAVEN
Signature: /s/ Dana Carrera, as manager of managing member
Signature date: 06 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PAVM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 912,996
Date: 27 Mar 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PAVM holding Derivative

Warrants

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 27 Mar 2026
Ownership: Direct
Underlying class: Series D Preferred Stock
Underlying amount: 5,365
Exercise price: $1000.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Warrant entitles the reporting person to purchase up to 5,365 shares of Series D Preferred Stock at an exercise price of $1,000 per share. Each share of Series D Preferred Stock has a stated value of $1,000 per share and is convertible into shares of Common Stock at a conversion price of $6.50 per share, for an aggregate of up to 825,385 shares of Common Stock. Upon exercise of the Warrant, the Issuer may, in lieu of issuing the Series D Preferred Stock, issue to the reporting person the number of shares of Common Stock that would be issuable to the holder upon conversion of the Series D Preferred Stock.